Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewJJKK 048 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor (IC50 = 0.4 nM). Exhibits >13,000 and ~630-fold selectivity for MAGL over FAAH and ABHD6, respectively. Increases brain levels of 2-arachidonoylglycerol (2-AG) levels in mice in vivo. Promotes analgesia in pain models.
JJKK 048 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 434.44 |
Formula | C23H22N4O5 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 1515855-97-6 |
PubChem ID | 76313567 |
InChI Key | CLSNATLUIXZPMV-UHFFFAOYSA-N |
Smiles | O=C(N6C=NC=N6)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)C1=CC(OCO4)=C4C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 43.44 | 100 |
The following data is based on the product molecular weight 434.44. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.3 mL | 11.51 mL | 23.02 mL |
5 mM | 0.46 mL | 2.3 mL | 4.6 mL |
10 mM | 0.23 mL | 1.15 mL | 2.3 mL |
50 mM | 0.05 mL | 0.23 mL | 0.46 mL |
References are publications that support the biological activity of the product.
Aaltonen et al (2013) Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. Chem.Biol. 20 379 PMID: 23521796
Laitinen et al (2014) Mutation of Cys242 of human monoacylglycerol lipase disrupts balanced hydrolysis of 1- and 2-monoacylglycerols and selectively impairs inhibitor potency. Mol.Pharmacol. 85 510 PMID: 24368842
Aaltonen et al (2016) In vivo characterization of the ultrapotent monoacylglycerol lipaseiInhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048). J.Pharmacol.Exp.Ther. 359 62 PMID: 27451409
If you know of a relevant reference for JJKK 048, please let us know.
Keywords: JJKK 048, JJKK 048 supplier, JJKK048, potent, selective, MAGL, inhibitors, inhibits, monoacylglycerol, lipases, hydrolases, analgesic, analgesia, 5206, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for JJKK 048 include:
Dandan et al (2017) Regulatory role of tumor necrosis factor receptor-associated factor 6 in breast cancer by activating the protein kinase B/glycogen synthase kinase 3β signaling pathway. Mol Med Rep 16 2269-2273 PMID: 28627683
Do you know of a great paper that uses JJKK 048 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review JJKK 048 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.